Dr. John P. Leonard, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Virginia School of Medicine (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 238
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: University of Virginia School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 186477 -
Internal Medicine Physician
NY license 186477 -
Medical Oncology Physician
NY license 186477
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- NYU Langone Hospitals New York, NY
- New York-Presbyterian Hospital New York, NY
Medical groups
- New York University (6,134 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 238
- Services billed
- 621
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 392 | 197 |
| Established patient office or other outpatient visit, 40-54 minutes | 167 | 61 |
| Established patient office or other outpatient visit, 20-29 minutes | 37 | 30 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 6 companies reported 13 payments worth $35,418 in total to this clinician.
| Genentech, Inc. | $18,265 |
|---|---|
| AstraZeneca UK Limited | $7,876 |
| Genentech USA, Inc. | $3,485 |
| Beone Medicines USA, Inc. | $2,600 |
| Regeneron Pharmaceuticals, Inc. | $1,622 |
| Kyowa Kirin, Inc. | $1,570 |
| Consulting Fee | $35,073 |
|---|---|
| Travel and Lodging | $329 |
| Food and Beverage | $15.77 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech, Inc. May 1, 2025 | Consulting Fee Columvi · BioOncology | $9,020 |
| AstraZeneca UK Limited Jan 16, 2025 | Consulting Fee CALQUENCE · Oncology | $4,110 |
| AstraZeneca UK Limited Jul 10, 2025 | Consulting Fee | $3,766 |
| Genentech USA, Inc. Jun 6, 2025 | Consulting Fee | $3,485 |
| Genentech, Inc. Jun 18, 2025 | Consulting Fee Actemra; Lunsumio · Immunology | $2,640 |
| Genentech, Inc. Apr 23, 2025 | Consulting Fee | $2,640 |
| Beone Medicines USA, Inc. Jun 24, 2025 | Consulting Fee BRUKINSA · Oncology | $2,600 |
| Genentech, Inc. Oct 8, 2025 | Consulting Fee | $1,980 |
| Genentech, Inc. Jun 12, 2025 | Consulting Fee Columvi · BioOncology | $1,640 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee | $1,622 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Genentech, Inc. Oct 8, 2025 | Consulting Fee | $1,980 |
| AstraZeneca UK Limited Jul 10, 2025 | Consulting Fee | $3,766 |
| Beone Medicines USA, Inc. Jun 24, 2025 | Consulting Fee BRUKINSA · Oncology | $2,600 |
| Genentech, Inc. Jun 18, 2025 | Consulting Fee Actemra; Lunsumio · Immunology | $2,640 |
| Genentech, Inc. Jun 12, 2025 | Consulting Fee Columvi · BioOncology | $1,640 |
| Genentech USA, Inc. Jun 6, 2025 | Consulting Fee | $3,485 |
| Genentech, Inc. May 1, 2025 | Consulting Fee Columvi · BioOncology | $9,020 |
| Genentech, Inc. May 1, 2025 | Travel and Lodging Columvi · BioOncology · travel to Boston, MA | $329 |
| Genentech, Inc. Apr 23, 2025 | Consulting Fee | $2,640 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee | $1,622 |
| Kyowa Kirin, Inc. Jan 30, 2025 | Consulting Fee | $1,570 |
| AstraZeneca UK Limited Jan 16, 2025 | Consulting Fee CALQUENCE · Oncology | $4,110 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $30,392 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Epizyme, Inc. · Active, not recruiting · NCT04224493
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.